Cancer diagnostics company Neoprobe has sold its radiation-detection device business to Devicor Medical Products in a deal that could reach a value as high as $50 million, reports MedCity News.
Devicor, a Wisconsin-based holding company backed by Chicago private equity firm GTCR Golder Rauner, has agreed to buy Neoprobe's device business for $30 million in cash and up to $20 million in royalty payments, according to a statement from Dublin, Ohio-based Neoprobe.
Read the full story here.